Tilray Launches Its Medical Cannabis Products Available in Australia Along with a Cannabis e-learning Platform
Tilray Brands, Inc. (NASDAQ: TLRY) TSX: TLRY), a leading Canadian cannabis company, incorporated in the U.S.A, with its headquarters in Toronto, Canada, announced the company’s expansion into Australia.
It is widening its range of medical cannabis products in Australia and is also introducing an e-learning platform of medical cannabis for healthcare professionals.
About Tilray Brands
Tilray Brands, Inc. is one of the global leaders in cannabis cultivation, production, distribution, and research. Besides the United States and Canada, where it is headquartered, the company has operations in New Zealand, Australia, Portugal, Germany, and Latin American countries.
Tilray is focused on improving people’s lives by making use of the healing potential of cannabis. Its production platform has more than 20 brands, spread out across more than 20 countries.
The product range includes, among other things, cannabis-based foods and beverages. Tilray’s medical cannabis products always maintain quality standards and are GMP-certified. Doctors, patients, hospitals, pharmacies, and researchers all over the world make use of them.
About Tilray’s Expansion in Australia
According to Denise Faltischek, who is the Head of International at Tilray, as well as its Chief Strategy Officer, Tilray is bringing about a global transformation of the cannabis industry through its scalable footprint and the range of its products.
As demand for medical cannabis products is increasing globally, the company is also evolving to cater to the new need by providing top-quality products and ensuring safe and easy access to these products to patients as well as healthcare workers.
She explained how the company had used its experiences from its German operations, along with patient feedback, to launch its new products in Australia to suit consumer requirements.
Australia’s Special Access Scheme (SAS) permits specified health practitioners to make use of medicines or medical devices, which may not be listed in the Australian Register of Therapeutic Goods (ARTG), for the requirement of a single patient.
Tilray’s range of products has been approved under this scheme. Its products are based mainly around modifications of whole flower selections and are of three types, having balanced, mid-range, and high THC levels. The option ‘balanced’ has THC and CBD in a ratio of 10:10, while ‘mid-range’ has 17:10, and ‘high’ has 25:10.
George Polimenakos, who is General Manager at Tilray ANZ, said that the company was committed to giving easy access to its products to patients who were in need of pharmaceutical-grade of medical cannabis and expressed his happiness at the company’s expansion to Australia. He also referred to the importance of incorporating cannabis education in the company’s operations, towards which they were introducing the new e-learning platform.
The platform is designed to make healthcare professionals understand the benefits of medical cannabis. Tilray had organized many workshops on medical cannabis for healthcare professionals across New Zealand and Australia in 2021.
Tilray also partners with research institutions to study the effects of medical cannabis. It works with Australia’s Murdoch Children’s Research Institute to study the possibility of using cannabis to treat children with behavioral problems resulting from intellectual disabilities.
With the cancer treatment center Chris O’Brien Lifehouse to develop a treatment for nausea resulting from chemotherapy, and with the University of Sydney to study how cannabis consumption affects driving.